most aCL detected with ELISA are directed against β2-glycoprotein I (β2-BPI), a 50-kDa plasma glycoprotein with anionic phospholipidsbinding properties. Antibodies directed against prothrombin and also β2-GPI account for the majority of LA activity. A variety of other antibodies against different phospholipid-binding proteins have been recently named (Table 1) but their pathogenic mechanisms and clinical meanings are still uncertain (4) .
There are some data coming from animal models, which support the pathogenic role of aPL. Mice immunized against β2-GPI (5) and with aPL antibodies (6) developed fetal loss. Also, mice infused with aPL developed significantly larger thrombi in femoral veins after experimental injury than mice infused with control antibodies (7) .
Different mechanisms by which aPLs can lead to thrombosis have been described. Some of them were investigated before the recent clarification of autoantibody specificities and this can explain the different results obtained. Moreover, it seems clear that thrombosis in APS is a "twohit" phenomenon. Antibodies-always present in blood-would cause a prothrombotic state but a second factor should be required to trigger thrombosis. Although speculative, this may include traumatic injury to the vascular bed, nonimmunologic procoagulant factors, or the presence of infection leading to cytokine production and endothelial cell activation (8) .
The diversity of antibodies and its specificities may also explain the wide spectrum of symptoms related to the presence of aPL and why some patients have only arterial thrombosis, others only venous thrombosis, or why only 30% of patients with positive aPL develop APS-related features.
The most likely mechanisms involving autoantibodies against phospholipid-binding proteins and leading to thrombosis can be classified as those by which aPLs interfere with hemostatic reactions (physiologic anticoagulant reactions and fibrinolysis) and those where antibodies induce cell-mediated events. The main cells involved are endothelial cells, monocytes, and platelets (4). This brief review is focused on mechanisms involving cell-mediated events.
ANTIPHOSPHOLIPID ANTIBODIES AND THE ENDOTHELIAL CELLS
Endothelial cell (EC) activation includes the change of its phenotype from antithrombotic to thrombotic, together with the production of adhesion molecules and cytokines. Several studies have investigated EC binding and activating properties of aPL antibodies. These studies showed binding of aPL to EC that might be mediated by β2-GPI (9,10). Anti-β2-GPI antibodies may bind to endothelial cells via β2-GPI bound to anionic phospholipids, such as phosphatidylserine in the cell membrane or to β2-GPI bound to β-receptor. Autoantibodies would transduce a signal by cross-linking of β-receptor or through binding to FcR, leading to the expression of adhesion molecules such as E-selectin, VCAM-1, and ICAM-1.
Increased expression of tissue factor (TF) in cultured vascular ECs by aPL has been described, with an increase in procoagulant activity (11) . TF is a specific transmembrane single-chain glycoprotein composed of 263 amino acids (47 kDa), that requires interaction with specific membrane phospholipids to become functionally active (12) (13) (14) . TF is widely accepted to be the major initiator of in vivo coagulation (15) . It is also believed that TF has a key role in fibrin deposition in immunologic disorders and can be induced, in vitro, to appear on endothelial cells and monocytes in a transcriptionally regulated manner by several physiologic or non-physiologic stimuli (16) (17) (18) . The same study describes an increase in monocyte adherence to EC, which also contributes to a hypercoagulable state and expression of adhesion molecules enhanced in EC. The interaction between endothelial and monocytic cells plays an important role in several thrombosis phases. A very recent study showed that monoclonal aCL and purified IgG fractions from patients with APS induce the production of monocyte chemoattractant protein-1 in human umbilical vein endothelial cells (HUVEC) (19) . The authors conclude that aCLs promote endothelial cell-monocyte cross-talk by enhancing the endothelial production of monocyte chemo- 
ANTIPHOSPHOLIPID ANTIBODIES AND MONOCYTES
A number of recent studies link aPL to increased procoagulant activity on circulating blood monocytes, inducing the expression of procoagulant activity of TF. In vitro, plasma from patients with APS can induce procoagulant activity in HUVEC (20) as well as increased TF expression in normal monocytes (21) . These effects seem to be restricted mostly to the plasma from patients with aPL and a history of thrombosis, whereas plasma from patients with aPL but no previous thrombosis could have no apparent effect (21) . A positive correlation was observed between the ability of APS plasma to promote TF-dependent procoagulant activity and monocyte TF expression and levels of plasma thrombinantithrombin III and prothrombin fragment 1 + 2, suggesting increased turnover of coagulation (21) .
In vivo, upregulation of TF pathway in patients with APS has also been described (22) (23) (24) . Our group has recently shown (23-25) that TFrelated procoagulant activity and TF mRNA levels in mononuclear blood cells, as well as the cell-surface expression of TF on monocytes, are increased in primary APS patients with thrombosis when compared with those without thrombosis and with healthy controls. TF expression in these patients has been found to be further increased in those positives for IgG aCL (23) .
The mechanisms by which aPL induce TF expression is unknown. The aCL responsible for the in vitro stimulation of TF exhibited anti-β2-GPI activity, and β2-GPI was present in the aCL-containing incubation media (22) . However, β2-GPI binding to membranes containing physiologic concentrations of anionic aPL appears to be relatively weak. Roubey has suggested that anti-β2-GPI antibodies could stabilize the β2-GPI-anionic interaction by cross-linking membrane-bound β2-GPI (4). Also, binding of aPL to PL-bound proteins on the cell surface, apart from mediating cell activation via the FcγRII, may be in itself a synergistic (or alternative) way by which aPL induces TF expression.
More recently, Annexin II, a phospholipidbinding protein, has been identified as an EC or monocyte surface molecule and might be in-volved in aPL-mediated cellular signaling, playing a critical role in the up-regulation of monocyte TF (26) .
At a molecular level, it has been suggested that aPL may interact with specific cell surface receptors (proteins and/or lipids), inducing signals that have consequences downstream, and that ultimately will result in up-regulation of cell surface proteins (i.e., TF). In an in vitro recent study, Pierangeli and associates demonstrated that aPL induces activation of the nuclear factor kappa by EC (27) . In turn, NFKB activation leads to upregulation of gene transcription of adhesion molecules on EC and to initiation of various signal transduction pathways.
ANTIPHOSPHOLIPID ANTIBODIES AND PLATELETS
How aPL interacts with platelets contributing to a hypercoagulable state is not fully understood. It seems that a previous stimulus that activates platelets is an essential step for aPL binding to the platelet surface. Normal platelet membrane shows a clear phospholipid asymmetry with phosphatidylserine predominantly located in the cytoplasmic leaftlet of the membrane. When platelets are activated, lose their physiologic phospholipid asymmetry, and increase the exposure of anionic phospholipids, mainly phosphotidylserine on the external membrane. Thus, circulating aCL/β2-GPI complexes might bind directly to phosphatidylserine on the activated platelet membrane (28) .
Numerous investigators have previously studied platelets' status in patients with aPL and some suggested that these antibodies may enhance thrombin-induced platelet activation/aggregation (29) .
Increased excretion of platelet-derived thromboxane urinary metabolites has been reported in aPL-positive patients who had antibodies to β2-GPI (30) . Also, the platelet activation markers CD62p and CD63 have been studied in aPL positive patients (31) . CD63 was significantly increased in patients with primary APS compared with healthy donors. There was no significant difference in median CD62p expression or percentage reticulated platelets between the two groups. Interestingly, CD63 values were lower in patients receiving aspirin, but aspirin did not prevent significant platelet activation occurring in some patients. Also, the median levels of P-selectin were significantly higher in patients than in controls. The lack of difference in platelet membrane CD62p expression may be explained because platelets expressing higher levels of CD62p might bind to monocytes and/or neutrophils and so excluded flow cytometry analysis. Platelet activation also leads to alterations in the GPIIb/IIIa receptor complex, formation of platelet-leukocyte aggregates and platelet-derived microparticles, although the molecular and cellular mechanism leading to the activation and regulation of these events remains unknown.
CONCLUSION
Thrombosis or pregnancy morbidiy and positivity of antiphospholipid antibodies define the features of antiphospholipid syndrome. Potential mechanisms of thrombosis in APS include aPL engagement of antigens on cell surfaces, leading to signal transduction and altered cell activity. This cell activation manifests in several ways, including enhanced adhesion molecule expression on endothelial cells, increased leukocyte adherence to ECs, increased procoagulant activity on ECs and monocytes, and enhanced thrombin-induced platelet activation/aggregation after aPL activation. Ongoing studies will show how each of these mechanisms contribute to the hypercoagulable state of patients with APS.
